GlassScriptPhysician profile
Cory Lewis Holt
NPI 1265059133
$1,052.57
in general payments reported to CMS, 2019-2025
33 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.74 · 2022: $153 · 2023: $151 · 2024: $287 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $71.18 | 2023-2025 | Rexulti |
| Eisai INC. | $69.75 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $60.27 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $58.04 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Viatris Specialty LLC | $57.88 | 2025 | Yupelri |
| Ardelyx, INC. | $50.08 | 2024-2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.92 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $42.59 | 2022-2024 | Injectafer |
| Lundbeck LLC | $38.07 | 2024-2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $37.03 | 2024-2025 | Hetlioz, Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $36.21 | 2022-2023 | |
| Axsome Therapeutics, INC. | $34.68 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $34.36 | 2024-2025 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $33.45 | 2021-2025 | Zoryve |
| Dexcom, INC. | $33.15 | 2024 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.49 | 2023-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $31.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $30.42 | 2022 | |
| Mylan Specialty L.P. | $26.66 | 2022-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $21.18 | 2023 | Xarelto |
| Edwards Lifesciences Corporation | $20.60 | 2025 | |
| Sumitomo Pharma America, INC. | $18.82 | 2024 | Gemtesa |
| Vertex Pharmaceuticals Incorporated | $18.08 | 2025 | |
| Glaxosmithkline, LLC. | $17.36 | 2025 | Trelegy Ellipta |
| Abbvie INC. | $16.79 | 2023 | |
| Seqirus USA INC | $16.48 | 2024 | Flucelvax, Fluad |
| Azurity Pharmaceuticals, INC. | $15.77 | 2023 | Edarbyclor |
| Novo Nordisk INC | $14.12 | 2022 | |
| Philips North America LLC | $14.01 | 2024 | (Ck6) Holter |
| Astrazeneca Pharmaceuticals LP | $13.95 | 2024 | Airsupra |
| Merck Sharp & Dohme LLC | $13.18 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.95 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.